Chen Xin, Kang Ying-Bo, Wang Li-Qing, Li Yun, Luo Yu-Wen, Zhu Zhe, Chen Rui
1 Department of Respiratory Diseases, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China ; 2 Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China ; 3 Department of Pharmacy, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China ; 4 Department of Respiratory Diseases, SUN Yat-sen Memorial Hospital, SUN Yat-sen University, Guangzhou 510120, China.
J Thorac Dis. 2015 Apr;7(4):644-52. doi: 10.3978/j.issn.2072-1439.2015.04.12.
Inhaled corticosteroids (ICSs) are widely used in combination with second controller medications in the management of asthma in adults and children. There lacks a systematic comparison between addition of leukotriene receptor antagonists (LTRAs) and theophylline to ICS. The purpose of this meta-analysis was to evaluate the difference of the efficacy and safety profile of adding either LTRAs or theophylline to ICS in adults and children with symptomatic asthma.
Randomised controlled trials (RCTs) published prior to November 2014 were acquired through systematically searching and selected based on the established inclusion criteria for publications. The data extracted from the included studies were further analyzed by a meta-analysis.
We included eight RCTs, of which six recruited adults and two recruited children aged 5 to 14 years. The primary outcomes were changes in lung function from baseline, including forced expiratory volume in the first second (FEV1) and peak expiratory flow (PEF). Overall, addition of LTRAs led to significantly better morning PEF {mean difference (MD) 16.94 [95% confidence interval (CI): 11.49-22.39] L/min, P<0.01} and FEV1 [MD 0.09 (95% CI: 0.03-0.15) L, P=0.005] as compared to addition of theophylline. There were no differences between the two treatments in terms of evening PEF, adverse events, rescue medication use and asthma exacerbation.
The combination of LTRA and ICS leads to modestly greater improvement in lung function than the combination of theophylline and ICS in the treatment of symptomatic asthma. Long-term trials are required to assess the efficacy and safety of these two therapies.
吸入性糖皮质激素(ICSs)广泛用于联合使用第二种控制药物来治疗成人和儿童哮喘。目前缺乏关于在ICS基础上加用白三烯受体拮抗剂(LTRAs)与加用茶碱之间的系统比较。本荟萃分析的目的是评估在有症状的成人和儿童哮喘患者中,在ICS基础上加用LTRAs或茶碱的疗效和安全性差异。
通过系统检索获取2014年11月之前发表的随机对照试验(RCTs),并根据既定的纳入标准进行筛选。从纳入研究中提取的数据进一步通过荟萃分析进行分析。
我们纳入了8项RCTs,其中6项招募成人,2项招募5至14岁儿童。主要结局指标是肺功能相对于基线的变化,包括第1秒用力呼气量(FEV1)和呼气峰值流速(PEF)。总体而言,与加用茶碱相比,加用LTRAs导致早晨PEF显著更好{平均差值(MD)16.94[95%置信区间(CI):11.49 - 22.39]L/min,P<0.01}以及FEV1[MD 0.09(95%CI:0.03 - 0.15)L,P = 0.005]。两种治疗在夜间PEF、不良事件、急救药物使用和哮喘急性加重方面无差异。
在治疗有症状的哮喘时,LTRA与ICS联合使用比茶碱与ICS联合使用能使肺功能有适度更大的改善。需要进行长期试验来评估这两种治疗方法的疗效和安全性。